The Diurnal and Nocturnal Effect of Travoprost With SofZia on Intraocular Pressure and Ocular Perfusion Pressure

PURPOSE: To determine the 24-hour effects of travoprost with sofZia on intraocular pressure (TOP) and ocular perfusion pressure as well as the endurance of TOP lowering after last dosing. " DESIGN: Prospective, open-label study. METHODS: Forty subjects with open-angle glaucoma or ocular hypertension were admitted to our sleep laboratory for three 24-hour sessions monitoring TOP, blood pressure (BP), and heart rate. The first baseline session occurred after medication washout or immediately after enrollment for treatment-naive patients. A second 24-hour monitoring session was performed after 4 weeks of once-nightly treatment of travoprost with sofZia. The medication was then discontinued and a third 24-hour session was completed 60-84 hours after the last dose taken. TOP measurements were taken using a pneumotonometer every 2 hours in the sitting position during the 16-hour diurnal period and in the supine position during the 8-hour nocturnal period. Ocular perfusion pressure was defined as 2/3 [diastolic BP + 1/3 (systolic BP - diastolic BP)] - TOP. RESULTS: Treatment with travoprost with sofZia significantly lowered mean diurnal and nocturnal TOP levels from baseline (diurnal 18.1 +/- 3.9 to 15.3 +/- 3.3 mm Hg; nocturnal 20.6 +/- 3.6 to 19.4 +/- 3.4 mm Hg, P < .01 for both). Once treatment was discontinued, mean TOP remained at levels significantly less than baseline during both the diurnal (16.6 +/- 3.8 mm Hg) and nocturnal periods (19.4 +/- 3.5 mm Hg). Mean baseline ocular perfusion pressure was significantly increased during the diurnal but not the nocturnal period (diurnal 73.7 +/-. 11.4 to 76.5 +/- 10.3 mm Hg, P = .01; nocturnal 64.4 +/- 12.6 to 64.2 +/- 11.1 mm Hg, P = .67). CONCLUSION: Travoprost with sofZia significantly lowers TOP throughout the diurnal and nocturnal periods, and increases ocular perfusion pressure in the diurnal, but not the nocturnal, period in open-angle glaucoma and ocular hypertension. The treatment effect on TOP endures for at least 84 hours after the last dose. (C) 2014 by Elsevier Inc. All rights reserved.